Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients

被引:19
|
作者
Clarke, Christina L. [1 ]
Kushi, Lawrence H. [2 ]
Chubak, Jessica [3 ]
Pawloski, Pamala A. [4 ]
Bulkley, Joanna E. [5 ]
Epstein, Mara M. [6 ,7 ]
Burnett-Hartman, Andrea N. [1 ]
Powell, Bethan [8 ]
Pearce, Celeste L. [9 ]
Feigelson, Heather Spencer [1 ]
机构
[1] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA
[2] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA
[3] Kaiser Permanente Washington, Hlth Res Inst, Seattle, WA USA
[4] HealthPartners Inst, Bloomington, MN USA
[5] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA
[6] Meyers Primary Care Inst, Worcester, MA USA
[7] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA
[8] Kaiser Permanente Northern Calif, Gynecol Oncol Program, San Francisco, CA USA
[9] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
关键词
D O I
10.1158/1055-9965.EPI-18-1324
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Relatively little is known about factors associated with long-term survival (LTS) following a diagnosis of ovarian cancer. Methods: We conducted a retrospective study of high-grade serous ovarian cancer (HGSOC) to explore predictors of LTS (defined as >= 7 years of survival) using electronic medical record data from a network of integrated health care systems. Multivariable logistic regression with forward selection was used to compare characteristics of women who survived >= 7 years after diagnosis (n = 148) to those who died within 7 years of diagnosis (n = 494). Results: Our final model included study site, age, stage at diagnosis, CA-125, comorbidity score, receipt of chemotherapy, BMI, and four separate comorbid conditions: weight loss, depression, hypothyroidism, and liver disease. Of these, only younger age, lower stage, and depression were statistically significantly associated with LTS. Conclusions: We did not identify any new characteristics associated with HGSOC survival. Impact: Prognosis of ovarian cancer generally remains poor. Large, pooled studies of ovarian cancer are needed to identify characteristics that may improve survival.
引用
收藏
页码:996 / 999
页数:4
相关论文
共 50 条
  • [41] Germline polymorphisms in cancer stem cell genes associate with survival among women with high-grade serous ovarian cancer
    Reid, Brett M.
    Permuth, Jennifer B.
    Chen, Zhihua
    Chen, Ann
    Sellers, Thomas A.
    CANCER RESEARCH, 2019, 79 (13)
  • [42] Multiple lines of chemotherapy for patients with high-grade ovarian cancer: Predictors for response and effect on survival
    Kessous, Roy
    Wissing, Michel D.
    Laskov, Ido
    Abitbol, Jeremie
    Bitharas, Joanna
    Agnihotram, Venkata R.
    Yasmeen, Amber
    Salvador, Shannon
    Lau, Susie
    Gotlieb, Walter H.
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (09) : 2304 - 2312
  • [43] T-cell activation is associated with high-grade serous ovarian cancer survival
    Wang, Lei
    Sun, Wenjie
    Zhang, Guoan
    Huo, Jingrui
    Tian, Yi
    Zhang, Yan
    Yang, Xiaohui
    Liu, Yingfu
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2022, 48 (08) : 2189 - 2197
  • [44] Nuclear SYK phosphorylation is associated with poor survival in high-grade serous ovarian cancer
    Yu, Y.
    Suryo, Y.
    Davidson, B.
    Africano, A. A.
    Fader, A. N.
    Wang, T. L.
    Shih, I. M.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 129 - 129
  • [45] IMPACT ON SURVIVAL OF INTEGRATIVE SYSTEMIC AND LOCAL METABOLOMICS IN HIGH-GRADE SEROUS OVARIAN CANCER
    Aust, S.
    Bachmayr-Heyda, A.
    Auer, K.
    Meier, S.
    Schmetterer, K.
    Dekan, S.
    Gerner, C.
    Pils, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 335 - 335
  • [46] Association of fusion genes with clinical outcomes and survival in high-grade serous ovarian cancer
    Newtson, A. M.
    Reyes, H. D.
    Lyons, Y. A.
    Cardillo, N. D.
    Russo, D.
    Devor, E.
    Goodheart, M. J.
    Gonzalez-Bosquet, J.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 103 - 104
  • [47] Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer
    Bachmayr-Heyda, Anna
    Aust, Stefanie
    Auer, Katharina
    Meier, Samuel M.
    Schmetterer, Klaus G.
    Dekan, Sabine
    Gerner, Christopher
    Pils, Dietmar
    CLINICAL CANCER RESEARCH, 2017, 23 (08) : 2081 - 2092
  • [48] IMPACT ON SURVIVAL OF INTEGRATIVE SYSTEMIC AND LOCAL METABOLOMICS IN HIGH-GRADE SEROUS OVARIAN CANCER
    Aust, S.
    Bachmayr-Heyda, A.
    Auer, K.
    Meier, S.
    Schmetterer, K.
    Dekan, S.
    Gerner, C.
    Pils, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1798 - 1798
  • [49] Wnt Signaling and Survival of Women With High-Grade Serous Ovarian Cancer A Brief Report
    Seagle, Brandon-Luke L.
    Dandapani, Monica
    Yeh, Judy Y.
    Shahabi, Shohreh
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (06) : 1078 - 1080
  • [50] Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients
    Anna P. Sokolenko
    Tatiana V. Gorodnova
    Ilya V. Bizin
    Ekaterina Sh. Kuligina
    Khristina B. Kotiv
    Alexandr A. Romanko
    Tatiana I. Ermachenkova
    Alexandr O. Ivantsov
    Elena V. Preobrazhenskaya
    Tatiana N. Sokolova
    Robert V. Broyde
    Evgeny N. Imyanitov
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 439 - 450